ALAN MOUDY: Open Payments
NPI 1316426257 · TALLAHASSEE, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$934 in 48 payments from 15 companies in 2025. Trend: 2023 $15 · 2024 $848 · 2025 $934
Food & beverage: $934
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $215 |
| AstraZeneca Pharmaceuticals LP | 8 | $153 |
| Esperion Therapeutics, Inc. | 5 | $89 |
| Amgen Inc. | 5 | $87 |
| Novo Nordisk Inc | 4 | $82 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $56 |
| PFIZER INC. | 2 | $38 |
| GlaxoSmithKline, LLC. | 2 | $34 |
| Lilly USA, LLC | 2 | $33 |
| Exact Sciences Corporation | 2 | $33 |
Products named: UBRELVY, NEXLETOL, OTEZLA, AIRSUPRA, VRAYLAR, XIFAXAN, BREZTRI, Wegovy.
Industry payments across FL — which companies pay providers there.
